Efficacy, safety and cost-effectiveness of chemo-immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated systematic review and cost-effectiveness analysis.

ABSTRACT:

Background

While toripalimab, camrelizumab and tislelizumab plus gemcitabine and cisplatin (TorGP, CamGP and TisGP) have been approved as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) in China, comprehensive comparisons of their relative clinical and economic value remain unavailable. Therefore, the objective of this study is to identify the most beneficial first-line treatment strategy for R/M NPC that balances efficacy, safety, and cost-effectiveness, thereby supporting informed clinical decision-making and efficient healthcare resource allocation.

Methods

A comprehensive systematic search was conducted across multiple databases-including PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov-for phase 3 randomized controlled trial

SUBMITTER: Qiu L 

PROVIDER: S-EPMC12605106 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature